Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 6/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.37 |
| ▸ | PARP1 | P09874 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17878877 | 0.97 | SMYD3 (0.41) | SMYD3LDHATNKSPARP2PARP1 | |
| SCHEMBL17878884 | 0.97 | SMYD3 (0.41) | SMYD3LDHATNKSPARP2PARP1 | |
| SCHEMBL17878871 | 0.96 | SMYD3 (0.41) | SMYD3LDHATNKSPARP2PARP1 | |
| SCHEMBL17878872 | 0.94 | DCPS (0.41) | SMYD3LDHATNKSPARP2PARP1 | |
| SCHEMBL17730317 | 0.93 | SMYD3 (0.44) | SMYD3LDHATNKSPARP2PARP1 | |
| SCHEMBL17740900 | 0.91 | SMYD3 (0.42) | SMYD3LDHATNKSPARP2PARP1 | |
| SCHEMBL17878864 | 0.91 | LDHA (0.43) | SMYD3LDHATNKSPARP2PARP1 | |
| SCHEMBL17740891 | 0.91 | SMYD3 (0.42) | SMYD3LDHATNKSPARP2PARP1 | |
| SCHEMBL17878876 | 0.91 | SMYD3 (0.42) | SMYD3LDHATNKSPARP2PARP1 | |
| SCHEMBL17740901 | 0.90 | LDHA (0.45) | SMYD3LDHATNKSPARP2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240065302-A1 | SWEETENER COMPOSITIONS COMPRISING MOGROSIDES AND USES THEREOF | FIRMENICH INCORPORATED | 2024-02-29 | — | — | US | disclosed |
| US-11339128-B2 | Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers | FIRMENICH INCORPORATED (US) | 2022-05-24 | — | — | US | disclosed |
| US-20180086751-A1 | SWEETENER COMPOSITION | SENOMYX, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20160185727-A1 | SUBSTITUTED 4-AMINO-5-(CYCLOHEXYLOXY)QUINOLINE-3-CARBOXYLIC ACIDS AS SWEET FLAVOR MODIFIERS | FIRMENICH INCORPORATED | 2016-06-30 | — | — | US | disclosed |
| WO-2016073251-A1 | SUBSTITUTED 4-AMINO-5-(CYCLOHEXYLOXY)QUINOLINE-3-CARBOXYLIC ACIDS AS SWEET FLAVOR MODIFIERS | SENOMYX, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339128-B2 | Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers | TAS2R5, TAS2R4, TAS2R30 | SMYD3 1526/4885LDHA 2337/4885TNKS 4707/4885 |
| US-20180086751-A1 | SWEETENER COMPOSITION | TAS2R50, TAS1R2, TAS2R10 | SMYD3 297/4885LDHA 1679/4885TNKS 4424/4885 |
| US-20160185727-A1 | SUBSTITUTED 4-AMINO-5-(CYCLOHEXYLOXY)QUINOLINE-3-CARBOXYLIC ACIDS AS SWEET FLAVOR MODIFIERS | TAS2R5, TAS2R4, TAS2R30 | SMYD3 1526/4885LDHA 2337/4885TNKS 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.